$2.20
-0.1-4.35%
Last update: Nov 10, 4:00 PM
BridgeBio Oncology Therapeutics Inc
BBOTNASDAQ
BridgeBio Oncology Therapeutics fell 82.0% from $12.75 to $2.30, behind the S&P 500's +9.8%. Its worst day was Sep 9 (−23.8%), and its low came Nov 6 at $2.04.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-1.03 missed the $-0.37 estimate on $0.00 revenue.
−2.0% · S&P 500 −1.7%
Story events cover the past 12 months · Times ET
BridgeBio Oncology Therapeutics shares rose 18.6%, while the S&P 500 rose 0.2%.
+18.6%, the year's best day · S&P 500 +0.2%
BridgeBio Oncology Therapeutics shares rose 12.2%, while the S&P 500 rose 0.0%.
+12.2% · S&P 500 0.0%
BridgeBio Oncology Therapeutics shares fell 13.2%, while the S&P 500 fell 1.2%.
−13.2% · S&P 500 −1.2%
EPS of $-0.49 beat the $-0.66 estimate on $0.00 revenue.
+5.4% · S&P 500 −1.3%
EPS of $-526.11 missed the $-0.51 estimate on $0.00 revenue.
−0.6% · S&P 500 +0.6%
EPS of $-705.20 missed the $-0.54 estimate on $0.00 revenue.
+2.4% · S&P 500 +0.3%
BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patientsBBO-8520 monotherapy continues to show highly competitive ORR in the 2L+
−23.8%, the year's worst day · S&P 500 −0.5%
BridgeBio Oncology Therapeutics shares fell 11.8%, while the S&P 500 fell 0.5%.
−11.8% · S&P 500 −0.5%
Where it ended: a close of $2.30 on Nov 9, 2026. Up next: Q4 2026 earnings on Mar 4, 2027 (EPS est. $-0.64).
Nothing in the past 12 months.
All BBOT dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BBOT and SPY from Benzinga historical bars. Not investment advice.
